1. In Vivo

IO Driving Surge In Number, Complexity Of Cancer Trials

 
• By John Hodgson

Nearly half of all late-stage cancer trials that started in 2015 had an antibody component, and 2016 brings the first full survival data from pivotal multi-checkpoint antibody trials. We document the immuno-oncology surge in data.

Research and development in oncology continues to expand rapidly. Some 5,906 clinical trials in cancer started between 2010 and 2015, according to Citeline's Trialtrove. (See Exhibit 1.) While the number of later-stage trials has remained relatively constant since 2012, the number of Phase I trials starting has tripled – from 120 in 2012 to over 380 in 2015 – concurrent with the influx of capital into the biotech sector.

SOURCE: Trialtrove

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Intelligence

More from In Vivo

Rising leaders 2025: Aneesh Karatt-Vellatt On Maxion Therapeutics’ Antibody Revolution

 
• By Jo Shorthouse

Aneesh Karatt-Vellatt is leading the charge to redefine how ion channels and G protein-coupled receptors (GPCRs) are targeted with antibody therapies, one of the most notoriously challenging classes of drug targets.

Podcast: Scancell’s Cancer Vaccine Progress With NHS Partnership

 
• By Jo Shorthouse

In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.

Geopolitical Volatility Not Dimming A Healthy Mid-Term Outlook For Life Sciences Deals

 
• By Ashley Yeo

New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.